Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Obeticholic acid
Drug ID BADD_D01592
Description Primary biliary cirrhosis, or PBC, is a progressive and chronic condition that leads to hepatic injury often resulting in end-stage liver failure that requires liver transplantation.[A192786] Obeticholic acid is a farnesoid-X receptor (FXR) agonist used to treat this condition, possibly allowing for increased survival.[A18696] In 2016, it was granted approval to treat primary biliary cholangitis in combination with [ursodeoxycholic acid], which was previously the mainstay treatment for this condition.[A18696,L12633] In May 2021, the FDA updated its prescribing information to contraindicate the use of obeticholic acid in patients with PBC and advanced cirrhosis (e.g. those with portal hypertension or hepatic decompensation) due to a risk of liver failure, in some cases requiring liver transplantation.[L34650] Obeticholic acid is currently being considered for FDA approval to treat fibrosis caused by non-alcoholic liver steatohepatitis (NASH). The NDA from Intercept Pharmaceuticals was approved in November 2019 and obeticholic acid is expected to be granted full approval for this indication in 2020.[L12636]
Indications and Usage Obeticholic acid was approved as an orphan drug based on its reduction in the level of the biomarker alkaline phosphatase as a surrogate endpoint for clinical benefit. It is indicated for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA. Additional studies are being required to prove its clinical benefit.
Marketing Status Prescription
ATC Code A05AA04
DrugBank ID DB05990
KEGG ID D09360
MeSH ID C464660
PubChem ID 447715
TTD Drug ID D0M4WA
NDC Product Code 73435-004; 63190-0840; 47848-056; 65089-0055; 0009-0098; 69766-066; 59285-028; 71796-004; 46708-923; 63190-0830; 69516-010; 68554-0121; 69516-005
Synonyms obeticholic acid | 6ECDCA | cholan-24-oic acid, 6-ethyl-3,7-dihydroxy-, (3alpha,5beta,6alpha,7alpha)- | 6alpha-ethyl-3alpha,7alpha-dihydroxy-5beta-cholan-24-oic acid | 6-ECDCA | 6alpha-ethyl-chenodeoxycholic acid | 6-ethyl-3,7-dihydroxycholan-24-oic acid | 6-ethyl chenodeoxycholic acid | 6-ethylchenodeoxycholic acid | DSP-1747 | DSP1747 | Ocaliva | INT 747 | INT747 | INT-747
Chemical Information
Molecular Formula C26H44O4
CAS Registry Number 459789-99-2
SMILES CCC1C2CC(CCC2(C3CCC4(C(C3C1O)CCC4C(C)CCC(=O)O)C)C)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
High density lipoprotein decreased13.12.01.0030.006307%Not Available
Hip fracture15.08.03.001; 12.04.01.0010.018921%
Hyperbilirubinaemia09.01.01.003; 01.06.04.003; 14.11.01.0100.010512%Not Available
Hyperhidrosis23.02.03.004; 08.01.03.0280.014717%
Hypersensitivity10.01.03.0030.039945%
Hypoaesthesia17.02.06.0230.021024%Not Available
Hypotension24.06.03.002--
Infection11.01.08.002--Not Available
Influenza22.07.02.001; 11.05.03.0010.023126%Not Available
Influenza like illness08.01.03.010--
Insomnia19.02.01.002; 17.15.03.0020.048355%
Intestinal obstruction07.13.01.0020.004205%Not Available
Irritability19.04.02.013; 08.01.03.011--
Jaundice01.06.04.004; 23.03.03.030; 09.01.01.0040.037843%Not Available
Joint swelling15.01.02.0040.018921%Not Available
Kidney infection20.01.09.004; 11.01.14.0060.006307%
Laboratory test abnormal13.18.01.0010.025229%Not Available
Libido decreased21.03.02.005; 19.08.03.0010.004205%
Liver disorder09.01.08.0010.021024%Not Available
Liver function test abnormal13.03.01.0130.014717%Not Available
Loss of consciousness17.02.04.004--Not Available
Low density lipoprotein increased13.12.01.0050.004205%Not Available
Malaise08.01.01.0030.075686%
Memory impairment19.20.01.003; 17.03.02.0030.025229%
Migraine24.03.05.003; 17.14.02.0010.012614%Not Available
Mood altered19.04.02.0070.008410%Not Available
Mood swings19.04.03.0010.006307%Not Available
Muscle spasms15.05.03.004--
Muscular weakness17.05.03.005; 15.05.06.0010.010512%
Myalgia15.05.02.001--
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 8 Pages